Vaxelis is a pediatric Hexavalent vaccine which includes antigens for diphtheria, tetanus, pertussis (whooping cough), and poliomyelitis from Sanofi and antigens for H. influenzae type b and hepatitis B from Merck.
Vaxelis is indicated for active immunization to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type b.
Vaxelis is approved for use in children from 6 weeks through 4 years of age (prior to the 5th birthday).
It is administered as a 3-dose immunization series as an intramuscular injection, at 2, 4, and 6 months of age.
On June 27, 2019, the US government’s vaccine advisory committee voted unanimously to include all parts of Vaxelis within the Vaccines for Children (VFC) program.
On December 26, 2018, The U.S. Food and Drug Administration approved Vaxelis.
Vaxelis was developed as part of a joint-partnership between Sanofi and Merck.